 |
| CardioMEMS HF System--Courtesy of St. Jude |
St. Jude Medical ($STJ) said in a new study that its CardioMEMS HF System can deliver improved outcomes and be cost-effective for heart failure patients who are already well-managed for their condition when they use pulmonary artery pressure monitoring.
The study focused on Class III heart failure patients who were already getting optimal treatment that included medical management with guideline directed medical therapy and device therapy using an implantable rhythm device, the company said in a press release.
"These data show a 43% reduction in heart failure hospitalizations and 53% reduction in mortality, which demonstrates the added value of PA (pulmonary artery) pressure monitoring in an already well managed patient population," William Abraham, chief of cardiovascular medicine at The Ohio State University Wexner Medical Center, said in a statement.
An economic analysis of the data from the Champion trial that was used to support FDA approval of the CardioMEMS HF system showed an Incremental Cost-Effectiveness Ratio (ICER) of $30,167 per quality adjusted life year for patients using pulmonary artery pressure monitoring, the company said.
In a separate announcement made at last week's Heart Rhythm Society conference in Boston, St. Jude Medical released new data on its quadripolar cardia resynchronization therapy pacemaker (CRT-P) system. The company said its Allure Quadra CRT-P, with its Quartet Quadripolar LV Lead is associated with a 63% reduction in the need to replace the lead or deactivate CRT following implant.
That study included more than 3,000 patients who had CRT-P implants of which 1,325 were a quadripolar lead and 1,930 had a bipolar lead.
- here are the pressure monitoring and lead releases